Furthermore, we observed that relapsing GC‐resistant patients with MS have decreased GR, DUSP1, and TSC22D3 mRNA levels compared with relapsing GC‐sensitive patients with MS. This evidence concerns the gene TSC22D3 and myeloid sarcoma.